Izba

Travoprost, the active ingredient in Izba, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for open‑angle glaucoma and ocular hypertension in adults. GNH USA supplies Izba as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Travoprost acts on the prostaglandin pathway to reduce intra‑ocular pressure in glaucoma‑related conditions. Open‑angle glaucoma: reduces eye pressure to slow optic nerve damage. Ocular hypertension: lowers pressure to prevent progression to glaucoma. Elevated intra‑ocular pressure: improves aqueous humor outflow to maintain normal pressure levels.

Travoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation or burning: transient discomfort after instillation. - Blurred vision: temporary visual disturbance. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris: gradual pigmentation change. - Eye discomfort: sensation of foreign body.

Serious or Rare Side Effects: - Ocular inflammation: uveitis or iritis requiring medical attention. - Macular edema: swelling of the central retina. - Severe allergic reaction: swelling, itching, or rash. - Vision loss: sudden decrease in visual acuity. - Persistent eye pain: may indicate complications.

Before using Travoprost, consider the following safety measures. Pregnancy: safety not established; avoid unless benefits outweigh risks. Breastfeeding: unknown excretion; use with caution. Concurrent ocular surgery: discontinue prior to procedure. Allergic history: assess for prostaglandin sensitivity. Contact lens wearers: remove lenses before instillation. Store below 25°C: keep in original container, protect from light and moisture.

Travoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may reduce efficacy. - Systemic carbonic anhydrase inhibitors: additive IOP‑lowering effect; monitor pressure. - Concurrent prostaglandin analogs: risk of excessive pressure reduction.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive pressure‑lowering effect. - Alpha‑agonist eye drops: may require pressure monitoring. - Topical corticosteroids: could counteract Travoprost’s effect.